A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors

NCT07291050 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: TQB3217Tablets

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.